27 March 2026 in Neuroradiology
18 April 2026 in Cancer Chemotherapy and Pharmacology
23 January 2026 in Acta Neurológica Colombiana
Background: Traumatic brain injury (TBI) remains a leading cause of long-term cognitive and functional impairment worldwide. Neurorehabilitation strategies have shown promise in promoting recovery, but the underlying structural brain changes remain poorly understood. Objective: To systematically evaluate the evidence for structural brain changes associated with neurorehabilitation interventions in patients with TBI, and their relationship with cognitive and functional recovery. Materials and methods: A systematic review was conducted according to PRISMA 2020 guidelines and registered in PROSPERO (CRD420251072783). A comprehensive search of PubMed, Scopus, Web of Science, MEDLINE and SciELO identified studies reporting neurorehabilitation interventions in TBI populations with structural neuroimaging outcomes. Study quality was assessed using the Newcastle–Ottawa Scale (NOS). Results: Eleven studies met the inclusion criteria. Interventions included cognitive training, neurologic music therapy, and multimodal programs. Most studies used MRI, DTI, or fMRI to assess neuroanatomical changes. Improvements were consistently observed in attention, memory, and executive function, often correlated with increased gray matter volume or enhanced functional connectivity in prefrontal and frontoparietal regions. NOS scores ranged from 2 to 9, with a median of 7. While methodological heterogeneity was present, most studies reported positive structural and clinical outcomes. Conclusion: Neurorehabilitation interventions may be associated with measurable changes in brain structure and connectivity, even in chronic TBI, supporting the concept of preserved neuroplasticity. These findings highlight the value of integrating neuroimaging into rehabilitation protocols to monitor and guide recovery. However, standardized methodologies and larger trials are needed to validate these effects and inform precision rehabilitation approaches.
1 April 2025 in Acta Neurológica Colombiana
Introduction: Neurodegenerative disorders (NDs), such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), and tauopathies are highly prevalent and cause significant public health concerns globally. Although research has focused on pathological proteins such as ?-amyloid, the growing interest in non-coding RNAs, including piRNAs, is shifting the understanding of neurodegenerative disorder mechanisms. Objective: This review aims to summarize the evidence of the role of piRNAs in neurodegenerative disorder pathogenesis and their potential as diagnostic biomarkers. Materials and methods: A systematic review was conducted following PRISMA guidelines. We included randomized controlled trials, cohort studies, and case-control studies focusing on piRNAs in neurodegenerative disorders. Data were extracted from PubMed and ScienceDirect using search terms related to piRNAs and neurodegenerative diseases published between 2009 and 2024. Results: Eleven studies met the inclusion criteria. These studies highlighted the dysregulation of piRNAs in diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, suggesting that piRNAs influence disease mechanisms by maintaining genomic stability, regulating transposable elements, and participating in protein degradation. Several piRNAs, including piR-hsa-92056, emerged as potential biomarkers with diagnostic accuracy. Discussion: The evidence underscores the crucial role of piRNAs in neurodegeneration. Mechanistic studies reveal that piRNA dysfunction may trigger cascades of genomic instability leading to neuronal death. piRNAs are emerging as valuable therapeutic targets and biomarkers in neurodegenerative disorders. Conclusions: piRNAs hold potential as innovative therapeutic and diagnostic tools in NDs. Future research should focus on developing piRNA-based interventions to prevent neurodegeneration.
30 November 2025 in Revista Colombiana de Hematología y Oncología
Introduction: Infantile high-grade gliomas are rare malignancies of the central nervous system (CNS) in children. Despite advancements, significant challenges remain in their treatment. A better understanding of their molecular biology may provide new therapeutic options. Clinical case: We report the case of a 30-month-old female diagnosed with an infantile high-grade glioma. Following urgent surgical resection, molecular analysis via a fusion panel identified a CLIP2-MET fusion mutation. This finding suggested potential treatment with crizotinib, a targeted therapy. However, several barriers delayed treatment initiation, including the lack of approval for crizotinib use in CNS tumors in Colombia and concerns about interactions with anticonvulsant therapy. Despite a brief period of clinical stability after initiating treatment, the patient unfortunately succumbed to the disease. Conclusion: Infantile high-grade gliomas pose significant therapeutic challenges, but identifying specific gene fusions, such as CLIP2-MET, may open new avenues for targeted therapy. This case underscores the need for regulatory adaptations to facilitate access to promising treatments when evidence supports their potential efficacy. To our knowledge, this is the first case in Colombia where an infantile glioma was treated with crizotinib, highlighting both the promise and the challenges of precision medicine in pediatric oncology.
2 October 2025 in Acta Neurológica Colombiana
Introduction: Diffuse gliomas are highly infiltrative brain tumors associated with poor prognosis and limited therapeutic response. Surgical resection remains a cornerstone of treatment, yet the balance between maximizing extent of resection (EOR) and preserving neurological function remains challenging. Advances in intraoperative technologies and molecular profiling have opened new possibilities for individualized treatment. Materials and methods: A systematic review was conducted in accordance with PRISMA guidelines. Studies evaluating surgical strategies—subtotal resection (STR), gross total resection (GTR), and supramaximal resection (SMR)—were included. Additionally, we assessed the prognostic and therapeutic implications of molecular biomarkers such as IDH mutations, MGMT promoter methylation, and 1p/19q codeletions. Results: IDH-mutant gliomas were consistently associated with longer overall survival and better responses to adjuvant therapies. MGMT promoter methylation correlated with improved overall survival in patients receiving temozolomide. Supramaximal resection outperformed gross total resection and subtotal resection in terms of progression-free and overall survival. Fluorescence-guided surgery and intraoperative imaging modalities reduced residual tumor volume, enhanced resection accuracy, and lowered complication rates. However, aggressive resections were linked to increased risk of postoperative neurological deficits. Discussion: Integrating surgical innovation with molecular characterization enables more precise and effective glioma management. While maximizing the extent of resection is beneficial oncologically, it must be weighed against potential functional impairment. Technological adjuncts can help mitigate this trade-off, especially in eloquent regions. Conclusions: Advanced surgical techniques combined with biomarker-driven strategies improve survival outcomes in diffuse gliomas. Personalized approaches are essential to tailor both surgical and adjuvant treatments, ultimately enhancing quality of life and extending survival.